Trials / Completed
CompletedNCT01591148
A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine how morbid obesity affects the distribution and metabolism of the drug propofol. The investigators hypothesize that propofol will be distributed and metabolized differently in morbidly obese subjects as compared to normal weight subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | propofol | Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2012-05-03
- Last updated
- 2017-12-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01591148. Inclusion in this directory is not an endorsement.